Biotechnology Products

  • B. L. Ferraiolo
  • R. J. Wills
  • M. A. Mohler
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 110)


This chapter is intended as an overview of the pharmacokinetics of biotechnology products. For the purposes of this chapter, biotechnology products will be defined as proteins (polypeptides larger than 5kDa) and antisense oligonucleotides. The interested reader is referred to other chapters in this volume (Chaps. 4 and 13) and other recent volumes and reviews (Ferraiolo et al. 1992; Garzone et al. 1991; Kung et al. 1992; McMartin 1992) for additional information.


Growth Hormone Human Growth Hormone Biotechnology Product Phosphorothioate Oligonucleotide Growth Hormone Binding Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595–7599PubMedCrossRefGoogle Scholar
  2. Ansher SS, Puri RK, Thompson WC, Habig WH (1992) The effects of interleukin-2 and alpha-interferon administration on hepatic drug metabolism in mice. Cancer Res 52: 262–266PubMedGoogle Scholar
  3. Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51: 531–554PubMedCrossRefGoogle Scholar
  4. Bachmair A, Finley D, Varshavsky A (1986) In vivo half life of a protein is a function of its amino terminal residue. Science 234: 179–186PubMedCrossRefGoogle Scholar
  5. Ballard FJ, Baxter RC, Binoux M, Clemmons DR, Drop SL, Hall K, Hintz RL, Rechler MM, Rutanen EM, Schwander JC (1990) Report on the nomenclature of the IGF binding proteins. J Clin Endocrinol Metab 70: 817–818CrossRefGoogle Scholar
  6. Baumann G, Shaw MA (1990) A second lower affinity growth hormone-binding protein in human plasma. J Clin Endocrinol Metab 70: 680–686PubMedCrossRefGoogle Scholar
  7. Baumann G, Stolar MW, Amburn K, Barsano CP, DeVries BC (1986) A specific growth hormone binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 62: 134–141PubMedCrossRefGoogle Scholar
  8. Baumann G, Amburn KD, Buchanan TA (1987) The effect of circulating growth hormone-binding protein on metabolic clearance, distribution and degradation of human growth hormone. J Clin Endocrinol Metab 64: 657–660PubMedCrossRefGoogle Scholar
  9. Baumann G, Shaw MA, Buchanan TA (1988) In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism 38: 330–333CrossRefGoogle Scholar
  10. Berger M, Halban PA, Girardier L, Seydoux J, Offord RE, Renold AE (1979) Absorption kinetics of subcutaneously injected insulin. Diabetologia 17: 97–99PubMedCrossRefGoogle Scholar
  11. Berger M, Cuppers HJ, Halban PA, Offord RE (1980) The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects. Diabetes 29: 81–83PubMedCrossRefGoogle Scholar
  12. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P (1982) Absorption kinetics and biological effects of subcutaneously injected insulin preparations. Diabetes Care 5: 77–91PubMedCrossRefGoogle Scholar
  13. Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6: 45–86PubMedCrossRefGoogle Scholar
  14. Bocci V (1987) Metabolism of protein anticancer agents. Pharmacol Ther 34: 1–49PubMedCrossRefGoogle Scholar
  15. Bocci V (1990) Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Del Rev 4: 149–169CrossRefGoogle Scholar
  16. Bocci V, Pacini A, Bandinelli L, Pessina GP, Muscettola M, Paulesu L (1982) The role of the liver in the catabolism of human alpha- and beta-interferons. J Gen Virol 60: 397–400PubMedCrossRefGoogle Scholar
  17. Bocci V, Muscettola M, Naldini A (1986a) The lymphatic route III pharmacokinetics of a human natural interferon-beta injected with albumin as a retarder in rabbits. Gen Pharmacol 17: 445–448PubMedGoogle Scholar
  18. Bocci V, Pacini A, Maioli E, Muscettola M, Paulesu L (1986b) Prolonged interferon plasma levels after administration of interferon with retarders. IRCS Med Sci 14: 360–361Google Scholar
  19. Chabot GG, Flaherty LE, Valdivieso M, Baker LH (1990) Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 27: 157–160PubMedCrossRefGoogle Scholar
  20. Chem T-L, Miller PS, Ts’o POP, Colvin OM (1990) Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection in mice. Drug Metab Dispos 18: 815–818PubMedGoogle Scholar
  21. Chipkin RE, Kreutner W, Billard W (1984) Potentiation of the hypoglycemic effect of insulin by thiorphan, an enkephalinase inhibitor. Eur J Pharmacol 102: 151–154PubMedCrossRefGoogle Scholar
  22. Clark RG, Jansson J-O, Isaksson O, Robinson ICAF (1985) Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol 104: 53–61PubMedCrossRefGoogle Scholar
  23. Clemmons DR (1989) The role of insulin-like growth factor binding proteins in controlling the expression of IGF actions. In: LeRoith D, Raizada MK (eds) Molecular and cellular biology of the insulin-like growth factors and their receptors.Google Scholar
  24. Cohen KL, Nissley SP (1976) The serum half life of somatomedin activity: evidence for growth hormone dependence. Acta Endocrinol 83: 243–258PubMedGoogle Scholar
  25. Cook JE, Ferraiolo BL, Mohler MA (1989) The role of binding proteins in the metabolism of IGF-I. Pharm Res 6: S30Google Scholar
  26. Craig PI, Mehta I, Murray M, McDonald D, Astrom A, van der Meide PH, Farrell GC (1990) Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Mol Pharmacol 38: 313–318PubMedGoogle Scholar
  27. Crooke RM (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des 6: 609–646PubMedGoogle Scholar
  28. Daggett V (1987) Protein degradation: the role of mixed-function oxidases. Pharm Res 4: 278–284PubMedCrossRefGoogle Scholar
  29. Danielpour D, Sporn MB (1990) Differential inhibition of transforming growth factor betal and beta2 activity by alpha2-macroglobulin. J Biol Chem 265: 6973–6977PubMedGoogle Scholar
  30. Davies JG, Offord RE, Halban PA, Berger M (1980) The chemical characterization of the products of the processing of subcutaneously injected insulin. In: Brandenburg D, Wollmer A (eds) Insulin—chemistry, structure and function of insulin and related hormones. De Gruyter, New York, p 517Google Scholar
  31. Echizen H, Ohta Y, Shirataki H, Tsukamoto K, Umeda N, Oda T, Ishizaki T (1990) Effects of subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis. J Clin Pharmacol 30: 562–567PubMedGoogle Scholar
  32. Fernandez-Botran R, Vitetta ES (1990) A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc Natl Acad Sci USA 87: 4202–4206PubMedCrossRefGoogle Scholar
  33. Ferraiolo BL, Mohler MA (1992) Goals and analytical methodologies for protein disposition studies. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Plenum, New YorkGoogle Scholar
  34. Ferraiolo BL, Fuller GB, Burnett B, Chan E (1988a) Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular and subcutaneous administration. J Biol Response Mod 7: 115–122PubMedGoogle Scholar
  35. Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H, Baughman RA (1988b) Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab Dispos 16: 270–275PubMedGoogle Scholar
  36. Ferraiolo BL, Cronin M, Bakhit C, Roth M, Chestnut M, Lyon R (1989) The pharmacokinetics and pharmacodynamics of a human relaxin in the mouse pubic symphysis bioassay. Endocrinology 125: 2922–2926PubMedCrossRefGoogle Scholar
  37. Ferraiolo BL, Mohler MA, Gloff CA (1992) Protein pharmacokinetics and metabolism. Plenum, New YorkGoogle Scholar
  38. Franklin MR, Finkle BS (1985) Effect of murine gamma-interferon on the mouse liver and its drug metabolizing enzymes: comparison with human hybrid alpha interferon J Interferon Res 5: 265–272PubMedCrossRefGoogle Scholar
  39. Franklin MR, Finkle BS (1986) The influence of recombinant DNA-derived human and murine gamma interferons on mouse hepatic drug metabolism. Fundam Appl Toxicol 7: 165–169PubMedCrossRefGoogle Scholar
  40. Freidenberg GR, White N, Cataland S, O’Dorisio TM, Sotos JF, Santiago JV (1981) Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N Engl J Med 305: 363–368PubMedCrossRefGoogle Scholar
  41. Fukuda MN, Sasaki H, Lopez L, Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84–89PubMedGoogle Scholar
  42. Garzone PD, Colburn WA, Mokotoff M (1991) Pharmacokinetics and pharmacodynamics: 3. Peptides, peptoids and proteins. Whitney, CinicinnatiGoogle Scholar
  43. Gatti G, Kahn J, Gambertoglio J (1991) Interspecies pharmacokinetic scaling for GLQ223. Clin Pharmacol Ther 49: 176Google Scholar
  44. Ghezzi P, Saccardo B, Bianchi M (1986) Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun 136: 316–321PubMedCrossRefGoogle Scholar
  45. Gloff CA, Benet LZ (1990) Pharmacokinetics and protein therapeutics. Adv Drug Del Rev 4: 359–386CrossRefGoogle Scholar
  46. Havredaki M, Barona F (1985) Variations in interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn J Med Sci Biol 38: 107–111PubMedGoogle Scholar
  47. Herington AC, Ymer S, Stevenson J (1986) Identification and characterization of specific binding proteins for growth hormone in normal human serum. J Clin Invest 77: 1817–1823PubMedCrossRefGoogle Scholar
  48. Higgins DL, Bennett WF (1990) Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmacol Toxicol 30: 91–121PubMedCrossRefGoogle Scholar
  49. Hodges TL, Kahn FO, Kaplan LD, Groopman JE, Volberding PA, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE, Allan JD (1991) Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother 35: 2580–2586PubMedGoogle Scholar
  50. Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429–453PubMedCrossRefGoogle Scholar
  51. Holford NHG, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16: 143–166PubMedCrossRefGoogle Scholar
  52. Hori R, Komada F, Okumura K (1983) Pharmaceutical approach to subcutaneous dosage forms of insulin. J Pharm Sci 72: 435–439PubMedCrossRefGoogle Scholar
  53. Hori R, Komada F, Iwakawa S, Seino Y, Okumura K (1989) Enhanced bioavailability of subcutaneously injected insulin coadministered with collagen in rats and humans. Pharm Res 6: 813–816PubMedCrossRefGoogle Scholar
  54. Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW (1988) The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 60: 255–261PubMedGoogle Scholar
  55. Isgaard J, Carlsson L, Isaksson OGP, Jansson J-O (1988) Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 123: 2605–2610PubMedCrossRefGoogle Scholar
  56. Iversen P (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des 6: 531–538PubMedGoogle Scholar
  57. Jonkman JHG, Nicholson KG, Farrow PR, Eckert M, Grassmijer G, Oosterhuis B, De Noord OE, Guentert TW (1989) Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 27: 795–802PubMedGoogle Scholar
  58. Kahn JO, Allen JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, Izu AE, Mordenti J, Sherwin SA, Groopman JE, Volberding PA (1990) The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome ( AIDS) and AIDS-related complex. Ann Intern Med 112: 254–261PubMedGoogle Scholar
  59. Klabunde RE, Burke SE, Henkin J (1990) Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb Res 58: 511–517PubMedCrossRefGoogle Scholar
  60. Komada F, Okumura K, Hori R (1985) Fate of porcine and human insulin at the subcutaneous injection site: II. In vitro degradation of insulins in the subcutaneous tissue of the rat. J Pharmacobiodyn 8: 33–40PubMedGoogle Scholar
  61. Koo PH, Stach RW (1989) Interaction of nerve growth factor with murine alphamacroglobulin. J Neurosci Res 22: 247–261PubMedCrossRefGoogle Scholar
  62. Kossiakoff A A (1988) Tertiary structure is a principal determinant of protein deamidation. Science 240: 191–194PubMedCrossRefGoogle Scholar
  63. Kroboth PD, Smith RB, Juhl RP (1988) Pharmacokinetics and pharmacodynamics: 2. Current problems/potential solutions. Whitney, CincinnatiGoogle Scholar
  64. Kung AHC, Larrick JW, Baughman RA (1992) Protein therapeutics: pharmacokinetics and pharmacodynamics. Stockton, New YorkGoogle Scholar
  65. LaMarre J, Wollenberg GK, Gauldie J, Hayes MA (1990) Alpha2-macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-beta2 on rat hepatocytes. Lab Invest 62: 545–551PubMedGoogle Scholar
  66. Lee VHL (1988) Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug Carrier Syst 5: 69–97PubMedGoogle Scholar
  67. Lelchuk R, Playfair JHL (1985) Serum IL-2 inhibitor in mice: I. Increase during infection. Immunology 56: 113–118PubMedGoogle Scholar
  68. Lim L, Spencer SA, McKay P, Waters MJ (1990) Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endrocrinology 127: 1287–1291CrossRefGoogle Scholar
  69. Lombardo YB, Morse EL, Adibi SA (1988) Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. J Biol Chem 263: 12920 - 12926PubMedGoogle Scholar
  70. Lucore CL, Sobel BE (1988) Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacological implications. Circulation 77: 660–669PubMedCrossRefGoogle Scholar
  71. Lucore CL, Fry ETA, Nachowiak DA, Sobel BE (1988) Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation. Circulation 77: 906–914PubMedCrossRefGoogle Scholar
  72. Maack T, Park CH, Camargo MJF (1985) Renal filtration, transport and metabolism of proteins. In: Seldin DW, Giebisch G (eds) The kidney: physiology and pathophysiology. Raven, New York, p 1773Google Scholar
  73. Maiter D, Underwood LE, Maes M, Davenport ML, Ketelslegers JM (1988) Different effects of intermittent and continuous growth hormone ( GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology 123: 1053–1059PubMedCrossRefGoogle Scholar
  74. Malik S, Lantz M, Slevin M, Olsson I (1991) Infusion of recombinant human tumour necrosis factor (rhTNF) causes an increase in circulating TNF-binding protein in man. Int J Exp Pathol 72: A6Google Scholar
  75. Maneval DC, Chen SA, Ferraiolo BL, Mordenti J, Clark R, Cook J, Mohler MA (1990) Pharmacokinetic/pharmacodynamic modeling of the hypoglycemic response to recombinant human insulin-like growth factor-I (rhIGF-I). American Association of Pharmaceutical Scientists 5th Annual Meeting, Symposium AbstractGoogle Scholar
  76. Mannor DA, Shaw MA, Winer LM, Baumann G (1988) Circulating growth hormonebinding proteins inhibit growth hormone ( GH) binding to GH receptors but not in vivo GH action. Clin Res 36: 870AGoogle Scholar
  77. Mazer NA (1990) Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery. J Control Rel 11: 343–356CrossRefGoogle Scholar
  78. McMartin C (1992) Pharmacokinetics of peptides and proteins; opportunities and challenges. Adv Drug Res 22: 39–106Google Scholar
  79. Mohler MA, Tate K, Bringman TS, Fuller G, Keyt B, Vehar G, Hotchkiss AJ (1988) Circulatory metabolism of recombinant tissue type plasminogen activator in monkeys and rabbits. Fibrinolysis 2: 17–23CrossRefGoogle Scholar
  80. Mohler MA, Cook J, Baumann G (1992) Binding proteins of protein therapeutics. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Plenum, New York, pp 35–71Google Scholar
  81. Mohler M, Cook J, Moore J, Lewis D, Sinicropi D, Championsmith A, Ferraiolo B (1993) Altered clearance of recombinant human deoxyribonuclease in rats due to the presence of a binding protein. Drug Metab Dispos 21: 71–75PubMedGoogle Scholar
  82. Moore JA, Marafino BJ, Stebbing N (1983) Influence of various purified interferons on effects of drugs in mice. Res Commun Chem Pathol Pharmacol 39: 113–125PubMedGoogle Scholar
  83. Moore JA, Vandlen R, McKay P, Spencer SA (1988) Serum clearance of human growth hormone bound to growth hormone binding protein. Endocrinology 122 [Suppl]: 121Google Scholar
  84. Moore JA, Celniker A, Fuh G, Light D, McKay P, Spencer S (1989) Cloned human growth hormone binding protein effects on disposition of human growth hormone in rats. Proc US Endocrine Soc 71: 435Google Scholar
  85. Mordenti J, Green JD (1991) The role of pharmacokinetics and pharmacodynamics in the development of the therapeutic proteins. In: Rescigno A, Thakur A (eds) New trends in pharmacokinetics. Plenum, New York, p 411Google Scholar
  86. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8: 1351–1359PubMedCrossRefGoogle Scholar
  87. Mordenti J, Shaieb D, Chow P, Cossum P, Ferraiolo B, Lewandowski M, Moore J, Green JD (1994) Preclinical safety evaluation strategy for biomacromolecules—a perspective. In: Gad SC (ed) Safety assessment for pharmaceuticals. Van Nostrand Reinhold, Princeton (in press)Google Scholar
  88. Mordenti J, Chen SA, Ferraiolo BL (1992) Pharmacokinetics of interferon-gamma. In: Kung AHC, Larrick JW, Baughman RA (eds) Therapeutics: protein pharmacokinetics and pharmacodynamics. New York, Freeman, pp 187–199Google Scholar
  89. Nokta M, Loh JP, Douidar SM, Ahmed EA, Pollard RB (1991) Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. J Interferon Res 11: 159–164PubMedCrossRefGoogle Scholar
  90. Offord RE, Philippe J, Davis JG, Halban PA, Berger M (1979) Inhibition of degradation of insulin by ophthalmic acid and a bovine pancreatic proteinase inhibitor. Biochem J 182: 249–251PubMedGoogle Scholar
  91. Okumura K, Komada F, Hori R (1985) Fate of porcine and human insulin at the subcutaneous injection site: I. Degradation and absorption of insulin in the rat. J Pharmacobiodyn 8: 25–32PubMedGoogle Scholar
  92. Ooi GT (1990) Insulin-like growth factor-binding proteins (IGFBPs): more than just 1,2,3. Mol Cell Endocrinol 7: C39–C43CrossRefGoogle Scholar
  93. Parkinson A, Lasker J, Kramer MJ, Huang M-T, Thomas PE, Ryan DE, Reik LM, Norman RL, Levin W, Conney AH (1982) Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metab Dispos 10: 579–585PubMedGoogle Scholar
  94. Parsons JA, Rafferty B, Stevenson RW, Zanelli JM (1979) Evidence that protease inhibitors reduce the degradation of parathyroid hormone and calcitonin injected subcutaneously. Br J Pharmacol 66: 25–32PubMedGoogle Scholar
  95. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weisinger J, Yacobi A (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 51: 465–474PubMedCrossRefGoogle Scholar
  96. Philip A, O’Connor-McCourt MD (1991) Interaction of transforming growth factorbetal with alpha2-macroglobulin. J Biol Chem 266: 22290–22296PubMedGoogle Scholar
  97. Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, Zanelli JM (1983) Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112: 1000–1006PubMedCrossRefGoogle Scholar
  98. Rogers S, Wells R, Rechsteiner M (1986) Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234: 364–368PubMedCrossRefGoogle Scholar
  99. Rosenbloom AL, Knuth C, Shulman D (1990) Growth hormone by daily injection in patients previously treated for growth hormone deficiency. South Med J 83: 653–655PubMedCrossRefGoogle Scholar
  100. Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU (1988) Interferoninduced changes in pharmacokinetics and tumor uptake of In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80: 160–165PubMedCrossRefGoogle Scholar
  101. Rustgi VK, Suou T, Jones DB, Lisker-Melman M, Vergalla J, Jones EA, Hoffnagle JH (1987) The effect of rat gamma interferon on antipyrine metabolism by the isolated perfused rat liver. Clin Res 35: 414AGoogle Scholar
  102. Secor J, Schenker S (1984) Effect of recombinant alpha-interferon on in vivo and in vitro markers of drug metabolism in mice. Hepatology 4: 1081Google Scholar
  103. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ (1987) Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. Life Sci 40: 2331–2336PubMedCrossRefGoogle Scholar
  104. Sherwood OD (1988) Relaxin. In: Knobil E, Neill J (eds) The physiology of reproduction. Raven, New York, p 585Google Scholar
  105. Singh G, Renton KW, Stebbing N (1982) Homogeneous interferon from E. coli depresses hepatic cytochrome P450 and drug biotransformation. Biochem Biophys Res Commun 106: 1256–1261PubMedCrossRefGoogle Scholar
  106. Sorensen JT, Colton CK, Hillman RS, Soeldner JS (1982) Use of a physiologic pharmacokinetic model of glucose homeostasis for assessment of performance requirements for improved insulin therapies. Diabetes Care 5: 148–157PubMedCrossRefGoogle Scholar
  107. Spivak JL, Hogans BB (1989) The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73: 90–99PubMedGoogle Scholar
  108. Stoudemire JB (1992) Pharmacokinetics and metabolism of hematopoietic proteins. In: Ferraiolo BL, Mohler MA, Gloff CA (eds) Protein pharmacokinetics and metabolism. Plenum, New York, pp 189–222Google Scholar
  109. Tam CS, Heersche JNM, Murray TM, Parsons J A (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110: 506–512PubMedCrossRefGoogle Scholar
  110. Taylor G, Marafino BJ, Moore JA, Gurley V, Blaschke TF (1985) Interferon reduces hepatic drug metabolism in vivo in mice. Drug Metab Dispos 13: 459–463PubMedGoogle Scholar
  111. Tuvemo T (1989) What is the best mode of growth hormone administration. Act Paediatr Scand Suppl 362: 44–49CrossRefGoogle Scholar
  112. Williams SJ, Farrell GC (1986) Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 22: 610–612PubMedGoogle Scholar
  113. Wills RJ (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390–399PubMedCrossRefGoogle Scholar
  114. Wills RJ (1994) Basic pharmacodynamic concepts and models. In: Cutler N, Narang PK (eds) Pharmacodynamics: perspectives in clinical pharmacology. Raven, New York (in press)Google Scholar
  115. Wilson JT (1970) Alteration of normal development of drug metabolism by injection of growth hormone. Nature 225: 861–863PubMedCrossRefGoogle Scholar
  116. Wilson JT, Frohman LA (1974) Concomitant association between high plasma levels of growth hormone and low mixed-function oxidase activity in the young rat. J Pharmacol Exp Ther 189: 255–270PubMedGoogle Scholar
  117. Wilton P, Widlund L, Guilbaud O (1987) Bioequivalence of Genotropin and Somatonorm. Acta Paediatr Scand Suppl 337: 118–121PubMedCrossRefGoogle Scholar
  118. Wilton P, Widlund L, Vangbo B (1988) Pharmacokinetics of recombinant human growth hormone in healthy volunteers (in press)Google Scholar
  119. Yamazoe Y, Shimada M, Kamataki T, Kato R (1986) Effects of hypophysectomy and growth hormone treatment on sex-specific forms of cytochrome P-450 in relation to drug and steroid metabolism in rat liver microsomes. Jpn J Pharmacol 42: 371 - 382PubMedCrossRefGoogle Scholar
  120. Young JD, Bell DP, Luo ZP, Marian M, Bauer R (1990) Comparative pharmacokinetics of lymphokines, cytokines and antibodies from mouse to man. Drug Information Association Workshop, nonclinical development isues for biotechnology-derived products, San DiegoGoogle Scholar
  121. Zapf J, Hauri C, Waldvogel M, Froesch ER (1986) Acute metabolic effects and half lives of intravenous insulin like growth factor I and II in normal and hypophysectomized rats. J Clin Invest 77: 1768–1775PubMedCrossRefGoogle Scholar
  122. Zapf J, Kiefer M, Merryweather J, Masiarz F, Bauer D, Born W, Fischer JA, Froesch ER (1990a) Isolation from adult human serum of four insulin-like growth factor ( IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. J Biol Chem 265: 14892–14898PubMedGoogle Scholar
  123. Zapf J, Schmid C, Binz K, Guler HP, Froesch ER (1990b) Regulation and function of carrier proteins for insulin-like growth factors. In: Sara VR (ed) Growth factors: from genes to clinical application. Raven, New York, p 227Google Scholar
  124. Zendegui JG, Vasquez KM, Tinsley JH, Kessler DJ, Hogan ME (1992) In vivo stability and kinetics of absorption and disposition of 3; phosphopropyl amino oligonucleotides. Nucleic Acids Res 20: 307–314PubMedCrossRefGoogle Scholar
  125. Zon G (1988) Oligonucleotide analogues as potential chemotherapeutic agents. Pharm Res 5: 539–549PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • B. L. Ferraiolo
  • R. J. Wills
  • M. A. Mohler

There are no affiliations available

Personalised recommendations